CLAIMS

What is claimed is:

1. A compound of formula

$$R^{5}$$
 R^{6}
 R^{6}
 R^{7}
 CH_{2}
 R^{2}
 R^{1}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{1}
 R^{2}

wherein

R¹ is aryl or heteroaryl;

R² is hydrogen, alkyl or cycloalkyl;

R³ is aryloxy, alkenyloxy, alkoxy or alkoxy substituted with one to three halogen atoms;

R⁴ is hydrogen, alkyl or cycloalkyl;

wherein any one of R5 and R6 is

and the other is hydrogen, alkyl or cycloalkyl and, wherein the bond between the carbon atoms C^a and C^b is a carbon carbon single or double bond;

R⁷ is hydrogen, alkyl or cycloalkyl;

R⁸ is hydrogen, alkyl or cycloalkyl;

wherein any one of A and A1 is nitrogen and the other is oxygen or sulfur;

n is 1, 2 or 3;

or a pharmaceutically acceptable salt or ester thereof.

2. The compound according to claim 1, wherein R^3 is alkoxy or alkoxy substituted with one to three halogen atoms; R^5 is

$$\begin{array}{c}
O & R^3 \\
C^{\frac{a}{2}} & C^{\frac{b}{2}}
\end{array}$$

wherein the bond between the carbon atoms C^a and C^b is a carbon carbon single or double bond;

R⁶ is hydrogen;

R⁷ is hydrogen;

R⁸ is hydrogen;

A is oxygen or sulfur; and

A¹ is nitrogen;

or a pharmaceutically acceptable salt or ester thereof.

- 3. The compound according to claim 1, wherein R¹ is thiophenyl or phenyl, each of which is optionally substituted with one to three substituents independently selected from halogen, alkoxy, alkyl and alkyl substituted with one to three halogen atoms.
- 4. The compound according to claim 3, wherein R¹ is thiophenyl, phenyl or phenyl substituted with one to three substituents independently selected from fluoro, chloro, methoxy, ethoxy, propyloxy, isopropyloxy, methyl, ethyl, propyl, isopropyl, tert.-butyl, and trifluoromethyl.
- 5. The compound according to claim 1, wherein R² is hydrogen, methyl or ethyl.
- 6. The compound according to claim 5, wherein R^2 is methyl.
- 7. The compound according to claim 1, wherein R³ is methoxy, ethoxy, propyloxy, isopropyloxy, phenoxy or butenyloxy.
- 8. The compound according to claim 7, wherein R^3 is methoxy or ethoxy.

- 9. The compound according to claim 1, wherein R^4 is hydrogen.
- 10. The compound according to claim 1, wherein R⁴ is methyl.
- 11. The compound according to claim 1, wherein the bond between the carbon atoms C^a and C^b is a carbon carbon single bond.
- 12. The compound according to claim 1, wherein R^6 is hydrogen.
- 13. The compound according to claims 1, wherein R^7 is hydrogen.
- 14. The compound according to claim 1, wherein R^7 is methyl.
- 15. The compound according to claim 1, wherein R⁸ is hydrogen.
- 16. The compound according to claim 1, wherein R⁸ is methyl.
- 17. The compound according to claim 1, wherein A is oxygen or sulfur and A^1 is nitrogen.
- 18. The compound according to claim 17, wherein A is oxygen.
- 19. The compound according to claim 1, wherein n is 1.
- 20. The compound according to claim 1 which is
- $(S)-3-\{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-2-ethoxy-propionic acid.\\$
- 21. The compound according to claim 1 which is
- $(S)-2-Ethoxy-3-\{1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-propionic acid.$

- 22. The compound according to claim 1 which is
- (S)-2-Ethoxy-3-{1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid.
- 23. The compound according to claim 1 which is (S)-3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid.
- 24. The compound according to claim 1 which is (S)-2-Ethoxy-3-{1-[2-(4-fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid.
- 25. The compound according to claim 1 which is rac-2-Ethoxy-3-{3-methyl-1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid.
- 26. The compound according to claim 1 which is rac-3-{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-3-methyl-1H-indol-5-yl}-2-ethoxy-propionic acid.
- 27. The compound according to claim 1 which is rac-2-Ethoxy-3-{1-[2-(4-fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-3-methyl-1H-indol-5-yl}-propionic acid.
- 28. The compound according to claim 1 which is rac-3-{1-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-propoxy-propionic acid.
- 29. The compound according to claim 1 which is rac-2-Isopropoxy-3-{1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid.

- 30. The compound according to claim 1 which is rac-2-But-3-enyloxy-3-{1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid.
- 31. The compound according to claim 1 which is rac-2-Ethoxy-3-{1-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-4-methyl-1H-indol-5-yl}-propionic acid.
- 32. The compound according to claim 1 selected from the group consisting of: rac-2-Ethoxy-3-[1-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid; (S)-2-Ethoxy-3-[1-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid; rac-2-Ethoxy-3-{1-[2-(2-fluro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}propionic acid; $rac-3-\{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-2-ethoxy-1-(2-Chloro-phenyl)-1$ propionic acid; rac-2-Ethoxy-3-[1-(5-methyl-2-o-tolyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid; $rac-2-Ethoxy-3-\{1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl-oxazol-4-ylmethyl-0xazol-4-y$ propionic acid; rac-2-Ethoxy-3-{1-[2-(2-isopropoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}propionic acid; propionic acid; $rac-2-Ethoxy-3-\{1-[2-(4-ethyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl]-1H-indol-5-yl$ propionic acid; and $(S)-2-Ethoxy-3-\{1-[2-(4-ethyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl\}-1H-indol-5-yl]-1H-indol-5-yl$ propionic acid
- 33. The compound according to claim 1 selected from the group consisting of: (R)-2-Ethoxy-3-{1-[2-(4-ethyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid; rac-2-Ethoxy-3-{1-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;

```
rac-3-{1-[2-(4-tert-Butyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
rac-2-Ethoxy-3-{1-[2-(4-fluoro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
rac-2-Ethoxy-3-{1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
rac-3-{1-[2-(3,5-Dimethyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
rac-3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
rac-3-{1-[2-(3,5-Difluoro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
rac-3-{1-[2-(3,5-Dichloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
rac-2-Ethoxy-3-{1-[2-(4-fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-5-yl}-1H-indol-
```

34. The compound according to claim 1 selected from the group consisting of: rac-2-Ethoxy-3-[1-(5-methyl-2-thiophen-2-yl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;

5-yl}-propionic acid.

- $\label{lem:condition} $$ \frac{1-[2-(3,4,5-trimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1$H-indol-5-yl}-propionic acid;$
- rac-2-Ethoxy-3-[1-(2-phenyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;
- rac-2-Ethoxy-3-[1-(2-phenyl-thiazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;
- rac-2-Ethoxy-3-[1-(5-methyl-2-phenyl-thiazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;
- rac-3-{1-[2-(4-Chloro-phenyl)-thiazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxy-propionic acid;
- (Z)-2-Methoxy-3-[1-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-acrylic acid; rac-2-Methoxy-3-[1-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;
- $(Z)-2-Methoxy-3-\{1-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethyl]-1H-indol-5-yl\}-acrylic acid; and$

rac-2-Methoxy-3-{1-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethyl]-1H-indol-5-yl}-propionic acid .

- 35. The compound according to claim 1 selected from the group consisting of: rac-2-Ethoxy-3-{1-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-3-methyl-1H-indol-5-yl}-propionic acid;
- rac-2-Ethoxy-3-{2-methyl-1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
- rac-2-Ethoxy-3-{1-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-2-methyl-1H-indol-5-yl}-propionic acid;
- rac-2-Ethoxy-3-{1-[2-(4-fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-2-methyl-1H-indol-5-yl}-propionic acid;
- rac-3-{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-2-methyl-1H-indol-5-yl}-2-ethoxy-propionic acid;
- rac-2-Ethoxy-3-[2-methyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid; rac-3-{1-[2-(4-tert-Butyl-phenyl)-oxazol-4-ylmethyl]-2-methyl-1H-indol-5-yl}-2-ethoxy-propionic acid;
- rac-3-[1-(5-Methyl-2-o-tolyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-2-propoxy-propionic acid;
- rac-3-{1-[2-(2-Methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-propoxy-propionic acid; and
- rac-3-{1-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-phenoxy-propionic acid.
- 36. The compound according to claim 1 selected from the group consisting of: rac-3-{1-[2-(4-Isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl}-1H-indol-5-yl}-2-phenoxy-propionic acid;
- rac-3-{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-phenoxy-propionic acid;
- rac-3-{1-[2-(4-Fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-phenoxy-propionic acid;
- rac-2-Isopropoxy-3-[1-(5-methyl-2-o-tolyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;

```
rac-2-Isopropoxy-3-{1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
rac-3-{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-isopropoxy-propionic acid;
rac-2-But-3-enyloxy-3-[1-(5-methyl-2-o-tolyl-oxazol-4-ylmethyl)-1H-indol-5-yl]-propionic acid;
rac-2-But-3-enyloxy-3-{1-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
rac-2-But-3-enyloxy-3-{1-[2-(2-chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid; and
rac-2-Ethoxy-3-{2-methyl-1-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethyl]-1H-indol-5-yl}-propionic acid.
```

- 37. The compound according to claim 1 selected from the group consisting of: rac-2-Ethoxy-3-{2-methyl-1-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-1H-indol-5-yl}-propionic acid;
- rac-2-Ethoxy-3-{4-methyl-1-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-1H-indol-5-yl}-propionic acid;
- $\label{lem:condition} $$ rac-2-Ethoxy-3-\{1-[2-(4-fluoro-3-methyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-4-methyl-1H-indol-5-yl\}-propionic acid;$
- $\label{lem:condition} $$ rac-3-\{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-4-methyl-1H-indol-5-yl\}-2-ethoxy-propionic acid;$
- $\label{lem:condition} $$ rac-3-\{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-4-methyl-1H-indol-5-yl\}-2-ethoxy-propionic acid;$
- rac-2-Ethoxy-3-{1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-1H-indol-5-yl}-propionic acid;
- (Z)-3-{1-[2-(2-Chloro-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-5-yl}-2-ethoxyacrylic acid;
- $\label{lem:condition} $$ \arc-2-Ethoxy-3-\{1-[2-(4-isopropyl-phenyl)-5-methyl-oxazol-4-ylmethyl]-1$H-indol-6-yl}-propionic acid;$
- rac-3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-6-yl}-2-ethoxy-propionic acid; and

rac-2-Ethoxy-3-{1-[2-(4-isopropyl-phenyl)-thiazol-4-ylmethyl]-1H-indol-6-yl}-propionic acid.

- 38. A pharmaceutical composition comprising a compound in accordance with claim 1 or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
- 39. The pharmaceutical composition of claim 38 further comprising a therapeutically effective amount of orlistat.
- 40. A method for the treatment of non-insulin dependent diabetes mellitus in a patient in need of treatment, comprising administering to said patient from about 0.1 mg to about 1000 mg per day of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 41. The method according to claim 40, wherein said compound or salt thereof is administered in an amount of from about 1 mg to about 100 mg per day.
- 42. The method according to claim 40, further comprising administering to said patient from 60 mg to 720 mg orlistat per day.